Jing Zhang

Jing Zhang

Auto-generated profile, based on publicly available information

Jing Zhang

McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI, United States

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Cell Metabolism
Verified
Journal Article
Closed access
SASheila A. Anderson
Sheila A. Anderson
CNChristopher P. Nizzi
Christopher P. Nizzi
YCYuan-I. Chang
Yuan-I. Chang
KDKathryn M. Deck
Kathryn M. Deck
PSPaul J. Schmidt
Paul J. Schmidt
RERichard S. Eisenstein
Richard S. Eisenstein

1 October 2012 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KJKirby D. Johnson
Kirby D. Johnson
AHAmy P. Hsu
Amy P. Hsu
MRMyung-Jeom Ryu
Myung-Jeom Ryu
JWJinyong Wang
Jinyong Wang
XGXin Gao
Xin Gao
EBEmery H. Bresnick
Emery H. Bresnick
Haploinsufficiency for GATA2 causes human immunodeficiency syndromes characterized by mycobacterial infection, myelodysplasia, lymphedema, or aplastic anemia that progress to myeloid leukemia. GATA2 encodes a master regulator of hematopoiesis that is also linked to endothelial biology. Though the disease-causing mutations commonly occur in the GATA-2 DNA binding domain, we identified a patient with mycobacterial infection and myelodysplasia who had an uncharacterized heterozygous deletion in a GATA2cis-element consisting of an E-box and a GATA motif. Targeted deletion of the equivalent murine element to yield homozygous mutant mice revealed embryonic lethality later than occurred with global Gata2 knockout, hematopoietic stem/progenitor cell depletion, and impaired vascular integrity. Heterozygous mutant mice were viable, but embryos exhibited deficits in definitive, but not primitive, hematopoietic stem/progenitor activity and reduced expression of Gata2 and its target genes. Mechanistic analysis revealed disruption of the endothelial cell transcriptome and loss of vascular integrity. Thus, the composite element disrupted in a human immunodeficiency is essential for establishment of the murine hematopoietic stem/progenitor cell compartment in the fetal liver and for essential vascular processes.

5 February 2009 in Blood
Verified
Journal Article
Closed access
PDF file
JZJing Zhang
Jing Zhang
JWJing Wang
Jing Wang
YLYangang Liu
Yangang Liu
HSHarwin Sidik
Harwin Sidik
KYKen H. Young
Ken H. Young
MFMark D. Fleming
Mark D. Fleming
KRAS is often mutated in human hematopoietic malignancies, including juvenile myelomonocytic leukemia (JMML) and T-cell lymphoblastic leukemia/lymphoma (TLL/L). However, the exact role and function of oncogenic KRAS mutations in the initiation and progression of JMML and TLL/L remain elusive. Here, we report the use of a mouse bone marrow transplantation model to study oncogenic Kras-induced leukemogenesis. We show that as the first genetic hit, oncogenic Kras mutations initiate both JMML and TLL/L, but with different efficiencies. Limiting dilution analyses indicated that an oncogenic Kras mutation alone is insufficient to produce frank malignancy. Instead, it cooperates with additional subsequent genetic event(s). Moreover, transplantation of highly purified hematopoietic stem cells (HSCs) and myeloid progenitors identified HSCs as the primary target for the oncogenic Kras mutation. Karyotypic analysis further indicated that secondary genetic hit(s) target lineage-specific progenitors rather than HSCs for terminal tumor transformation into leukemic stem cells. Thus, we propose the cellular mechanism underlying oncogenic Kras-induced leukemogenesis, with HSCs as the primary target by the oncogenic Kras mutations and lineage-committed progenitors as the final target for cancer stem cell transformation. Our model might be also applicable to other solid tumors harboring oncogenic Kras mutations.

23 December 2010 in Blood
Verified
Journal Article
Open access
PDF file
JWJinyong Wang
Jinyong Wang
YLYangang Liu
Yangang Liu
ZLZeyang Li
Zeyang Li
JDJuan Du
Juan Du
MRMyung-Jeom Ryu
Myung-Jeom Ryu
JZJing Zhang
Jing Zhang
Oncogenic NRAS mutations are frequently identified in myeloid diseases involving monocyte lineage. However, its role in the genesis of these diseases remains elusive. We report a mouse bone marrow transplantation model harboring an oncogenic G12D mutation in the Nras locus. Approximately 95% of recipient mice develop a myeloproliferative disease resembling the myeloproliferative variant of chronic myelomonocytic leukemia (CMML), with a prolonged latency and acquisition of multiple genetic alterations, including uniparental disomy of oncogenic Nras allele. Based on single-cell profiling of phospho-proteins, a novel population of CMML cells is identified to display aberrant granulocyte-macrophage colony stimulating factor (GM-CSF) signaling in both the extracellular signal-regulated kinase (ERK) 1/2 and signal transducer and activator of transcription 5 (Stat5) pathways. This abnormal signaling is acquired during CMML development. Further study suggests that aberrant Ras/ERK signaling leads to expansion of granulocytic/monocytic precursors, which are highly responsive to GM-CSF. Hyperactivation of Stat5 in CMML cells is mainly through expansion of these precursors rather than up-regulation of surface expression of GM-CSF receptors. Our results provide insights into the aberrant cytokine signaling in oncogenic NRAS-associated myeloid diseases.

18 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRyan M. Carr
Ryan M. Carr
DVDenis Vorobyev
Denis Vorobyev
TLTerra Lasho
Terra Lasho
DMDavid L. Marks
David L. Marks
ETEzequiel Tolosa
Ezequiel Tolosa
MPMrinal M. Patnaik
Mrinal M. Patnaik
Proliferative chronic myelomonocytic leukemia (pCMML), an aggressive CMML subtype, is associated with dismal outcomes. RAS pathway mutations, mainly NRASG12D, define the pCMML phenotype as demonstrated by our exome sequencing, progenitor colony assays and a Vav-Cre-NrasG12D mouse model. Further, these mutations promote CMML transformation to acute myeloid leukemia. Using a multiomics platform and biochemical and molecular studies we show that in pCMML RAS pathway mutations are associated with a unique gene expression profile enriched in mitotic kinases such as polo-like kinase 1 (PLK1). PLK1 transcript levels are shown to be regulated by an unmutated lysine methyl-transferase (KMT2A) resulting in increased promoter monomethylation of lysine 4 of histone 3. Pharmacologic inhibition of PLK1 in RAS mutant patient-derived xenografts, demonstrates the utility of personalized biomarker-driven therapeutics in pCMML.

3 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AVAlicia Villatoro
Alicia Villatoro
VCVincent Cuminetti
Vincent Cuminetti
ABAurora Bernal
Aurora Bernal
CTCarlos Torroja
Carlos Torroja
ICItziar Cossío
Itziar Cossío
LALORENA ARRANZ
LORENA ARRANZ
Here we explored the role of interleukin-1β (IL-1β) repressor cytokine, IL-1 receptor antagonist (IL-1rn), in both healthy and abnormal hematopoiesis. Low IL-1RN is frequent in acute myeloid leukemia (AML) patients and represents a prognostic marker of reduced survival. Treatments with IL-1RN and the IL-1β monoclonal antibody canakinumab reduce the expansion of leukemic cells, including CD34+ progenitors, in AML xenografts. In vivo deletion of IL-1rn induces hematopoietic stem cell (HSC) differentiation into the myeloid lineage and hampers B cell development via transcriptional activation of myeloid differentiation pathways dependent on NFκB. Low IL-1rn is present in an experimental model of pre-leukemic myelopoiesis, and IL-1rn deletion promotes myeloproliferation, which relies on the bone marrow hematopoietic and stromal compartments. Conversely, IL-1rn protects against pre-leukemic myelopoiesis. Our data reveal that HSC differentiation is controlled by balanced IL-1β/IL-1rn levels under steady-state, and that loss of repression of IL-1β signaling may underlie pre-leukemic lesion and AML progression.